


Supplementary figures




sFig.1 The morphological changes of NSCLC H460 cells induced by TNF- α and TGF- β before (A) and after (B) incubation The epithelial cells got transition to mesenchymal cell shape in the presence of TNF- α and TGF- β . (Magnification: 20x).




sFig.2 incubation of TNF- α and TGF- β promote expression of stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 in non-small cell lung cancer cells H460. The protein expression level was normalized by β -actin. * P<0.05, compared to untreated cells. # P<0.05, compared to TGF β alone.




sFig.3 BrMC inhibit stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 in H460 stem cells induced by TNF- α and TGF- β . The protein expression level was normalized by β -actin. * P<0.05, compared to untreated cells. # P<0.05, compared to BrMC (1.0 μ mol/L) treatment.




sFig.4 Suppression of NF κ B by SN50 can enhance the inhibition of BrMC on non-small lung cancer stem cells. Expression of cancer stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 were analyzed by western blot, and the protein expression level was normalized by β -actin. * P<0.05, compared to untreated cells. # P<0.05, compared to SN50 (10.0 μ mol/L) treatment only.



sFig.5 Suppression of FoxM1 by thiostrepton can enhance the inhibition of BrMC on non-small lung cancer stem cells. Expression of cancer stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 were analyzed by western blot, and the protein expression level was normalized by β -actin. * P<0.05, compared to untreated cells. # P<0.05, compared to THI (10.0 μ mol/L) treatment only.



sFig.6 Overexpression of NF κ B-p65 compromised the inhibition of BrMC on non-small lung cancer stem cells. Expression of cancer stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 were analyzed by western blot, and the protein expression level was normalized by β -actin. * P<0.05, compared to cells with vectors. # P<0.05, compared to cells with vectors and treated by BrMC (5.0 μ mol/L).



sFig.7 Overexpression of FoxM1 compromised the inhibition of BrMC on non-small lung cancer stem cells. Expression of cancer stem cell marker (CD133, CD44, OCT4, Bmi1), NF κ B and FoxM1 were analyzed by western blot, and the protein expression level was normalized by β -actin. * P<0.05, compared to cells with vectors. # P<0.05, compared to cells with vectors and treated by BrMC (5.0 µmol/L).